Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Patrys secures funding of up to A$15 million to support advancement of clinical products

Patrys Limited (ASX: PAB), a company focused on the development of natural human antibodies for the treatment of cancer, announced today that it has secured up to A$15 million in funding.

3 Aug 2010

Research findings could lead to new drugs that reduce severity of blood infections leading to sepsis

Scientists have made an important discovery that could lead to new drugs that reduce the severity of blood infections leading to sepsis. Research presented in the August 2010 issue of Journal of Leukocyte Biology shows how interfering with the function of the cell membrane protein called "Programmed Death 1" (PD-1) improves survival in a clinically relevant model of severe infection.

2 Aug 2010

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen Corporation today announced that the Company has received three additional grants to support its research program to develop HDAC inhibitors for neurodegenerative diseases. Repligen has received $436,000 in research funding to support the ongoing development of histone deacetylase inhibitors for Friedreich's ataxia.

2 Aug 2010

New website of MultiCell Technologies launched with a fresh new look

MultiCell Technologies, Inc. has launched a new website with a fresh new look and updated information about discovery technology platforms and lead drug candidates. It also provides information to answer investors' most common questions.

31 Jul 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

Measuring GAPDH inhibiting antibodies can result in long-term treatment for MS

UCI immunologists have found that testing for increased levels of antibodies that inhibit energy production in neurons can detect axon and neuron degeneration in multiple sclerosis earlier than existing diagnostic tools.

31 Jul 2010

Scientists identify enzyme to prevent beta-amyloids formation in Alzheimer patients

The brains of Alzheimer patients have high accumulations of the material beta-amyloid, which appear in the form of plaques. The precursors of these plaques are believed to be the underlying cause of the nerve cell loss that leads to the disruptions in memory that characterize Alzheimer's disease. The main aim of many Alzheimer therapies is therefore to inhibit the formation of beta-amyloid. Since beta-amyloid is cleaved from the so-called amyloid precursor protein (APP), scientists have focused on stopping the two enzymes that attack the precursor protein. These act like molecular scissors and cut out the beta-amyloid fragment. Blocking these scissors precludes the formation of beta-amyloid.

31 Jul 2010

Ten steps to successful breastfeeding from WHO and UNICEF

During World Breastfeeding Week, celebrated from 1 to 7 August in more than 170 countries, WHO reiterates its call on health facilities and health workers to implement ten steps to help mothers breastfeed successfully and improve their babies' health and chances of survival.

30 Jul 2010

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Cancer Research UK's Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today (Friday) with the manufacture of its first product - an antibody for treating a range of cancers.

30 Jul 2010

Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.

30 Jul 2010

SeraCare Life Sciences launches new product to diagnose HIV

SeraCare Life Sciences, Inc. today announced that the Company has launched a set of new products in its diagnostic controls and panels portfolio—the SeraCare HIV-1 Seroconversion Panels. Each of the six panels consists of a set of undiluted plasma samples from a single plasma donor collected over a period of time during the development of detectable specific antibodies to HIV in the blood, or seroconversion, and is highly characterized with enhanced product information.

30 Jul 2010

Quidel second-quarter total revenues increase 1.6% to $25.0 million

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today financial results for the second quarter ended June 30, 2010.

30 Jul 2010

EMA recommends orphan medicinal product designation for XOMA 052 in treatment of Behcet's disease

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease. Positive opinions are submitted to the European Commission for decision and are generally adopted within 30 days of receipt.

29 Jul 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

China PharmaHub to close Merger Agreement with World Wide Relics in August 2010

China PharmaHub Corp., a pharmaceutical HUB between Chinese pharmaceutical companies and other pharmaceutical companies located worldwide, announced today that it has entered into a Merger Agreement with World Wide Relics, Inc.. The merger is expected to close in August 2010.

29 Jul 2010

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

29 Jul 2010

Pain Therapeutics second-quarter collaboration revenue decreases to $0.1 million

Pain Therapeutics, Inc., a biopharmaceutical company, today reported second quarter financial results. Net loss for the quarter ended June 30, 2010 was $0.8 million, or $0.02 per share, compared to net loss of $34,000, or $0.00 per share, for the second quarter of 2009. Pain Therapeutics had cash, cash equivalents and marketable securities of $176.2 million, or about $4.14 cash per share, and no debt as of June 30, 2010.

28 Jul 2010